BN
Barzin Nabet
Also known as: Barzin Y Nabet
Genentech Inc, Stanford University, University of Pennsylvania
Research areas: Medicine · Oncology · Cancer Immunotherapy and Biomarkers · Lung Cancer Treatments and Mutations · T-cell and B-cell Immunology
0000-0002-4824-3533
Employment
-
Genentech Inc Senior Principal Scientist2020 - Present
-
Stanford University Postdoctoral Scholar2017 - Present
-
University of Pennsylvania Research Specialist, Pittman Laboratory2010 - 2011
Education
- 2011 - 2017
- 2006 - 2010
Projects & Funding
-
Stroma-mediated mechanisms of breast cancer treatment resistance National Cancer Institute2014 - 2017
Publications (104)
- Supplementary Figure S1 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S10 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S11 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S12 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S13 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S2 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S3 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S4 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S5 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S6 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S7 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S8 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Figure S9 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Table S1 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Table S2 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Table S3 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Table S4 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Table S5 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- Supplementary Table S6 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation Save
- VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC Save